GLI1, a terminal effectors of the HH factors, was reported to serve as an oncogene in wide ranges of cancers, such as breast cancer (47), CRC (48), prostate cancer (49), glioma (50), pancreatic cancer (51), gastric cancer (52), and cervical cancer (53). This evidence concerns the gene GLI1 and breast cancer.